A Phase 2 interventional study of PF-04171327 10 mg and Prednisone Placebo in Rheumatoid Arthritis, sponsored by Pfizer. Completed at 41 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-22.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
This study will investigate the safety and efficacy of an investigational drug, PF-04171327 on the signs and symptoms of rheumatoid arthritis in patients that require glucocorticoids while on background methotrexate. This study will also look at the response of chemical and biological markers in rheumatoid arthritis patients. Lastly, this study will measure the PK (amount of drug in the blood) of methotrexate while patients may be taking PF-04171327.
2,962 studies on the registry are indexed under Arthritis, Rheumatoid; 396 are open to participants now.
This study's enrollment of 86 is close to the median of 94 across 2,027 interventional studies indexed under Arthritis, Rheumatoid.
Browse Arthritis, Rheumatoid studies →Pfizer is the lead sponsor of 3,323 studies on the registry; 145 are open to participants now.
Of its 597 completed or terminated interventional studies of FDA-regulated products, 391 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: PF-04171327 10 mg · Other: Prednisone Placebo
Drug: PF-04171327 25 mg · Other: Prednisone Placebo
Drug: Prednisone 5 mg · Other: Placebo for PF-04171327
Other: Placebo · Other: Placebo for PF-04171327
PF-04171327 10 mg tablet every day for 14 days
Placebo for Prednisone 5 mg tablet every day for 14 days
PF-04171327 25 mg tablet every day for 14 days
Placebo for Prednisone 5 mg tablet every day for 14 days
Prednisone 5 mg tablet every day for 14 days
Placebo for PF-04171327 every day for 14 days
Placebo tablet every day for 14 days
Placebo tablet every day for 14 days
Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (4 Variables) (DAS28-4 [CRP]) at Day 14
DAS28-4 (CRP) examines progression or improvement of RA. It was assessed from swollen joint count (SJC) and tender joint count (TJC) using the 28 joints count, CRP (normal range of CRP is less than (\<) 10 milligram per liter \[mg/L\], decrease in the level of CRP indicates reduction in inflammation) and participant global assessment (PGA) of disease activity (participant global assessment of diseases condition scores ranging from 0 \[very well condition\] to 100 \[very poor condition\], higher scores indicated greater affectation due to disease activity). Total DAS28-4 (CRP) transformed score range: 0 (least severe) to 10 (most severe), higher scores indicate more severe disease activity. DAS28-4 (CRP) scores: less than equal to (\<=) 3.2 implied low disease activity; greater than (\>) 3.2 to 5.1 implied moderate to high disease activity.
Time frame: Baseline, Day 14
Change From Baseline in Tender Joints Count at Day 7, 14, 42
Number of tender joints was determined by examining 28 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1.
Time frame: Baseline, Day 7, 14, 42
Change From Baseline in Swollen Joints Count at Day 7, 14 and 42
Number of swollen joints was determined by examination of 28 joints and identifying if swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1.
Time frame: Baseline, Day 7, 14, 42
Change From Baseline in C-Reactive Protein (CRP) at Day 7, 14 and 42
The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. Normal range of CRP is less than (\<) 10 mg/L. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.
Time frame: Baseline, Day 7, 14, 42
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Day 7 and 14
HAQ-DI assessed the ability of participants to perform task in 8 domains of daily living activities: dress/groom, arise, eat, walk, reach, grip, hygiene, and common activities. Each item was scored on a 4-point scale ranging from 0 to 3: 0= no difficulty; 1= some difficulty; 2= much difficulty; 3= unable to do, higher scores indicate more difficulty. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible HAQ-DI score range: 0 (no difficulty) to 3 (extreme difficulty), where higher scores indicate more difficulty while performing daily living activities.
Time frame: Baseline, Day 7, 14
Change From Baseline in Participant Assessment of Arthritis Pain at Day 7 and 14
Participant assessment of arthritis pain included assessment of severity of arthritis pain using a 100 millimeter (mm) visual analog scale (VAS). Participants placed a mark on the VAS between 0 mm (no pain) and 100 mm (most severe pain), which corresponded to the magnitude of their pain, higher scores indicate more pain.
Time frame: Baseline, Day 7, 14
Change From Baseline in Participant Global Assessment (PGA) of Arthritis at Day 7 and 14
PGA was a questionnaire where participants answered the following question, "Considering all the ways your arthritis affects you, how are you feeling today?" The participants' response were recorded using a 100 mm visual analog scale placing a mark on the scale, between 0 mm (very well condition) to 100 mm (very poor condition). Higher scores indicate higher degree of arthritis.
Time frame: Baseline, Day 7, 14
Change From Baseline in Physician Global Assessment (PhGA) of Arthritis at Day 7 and 14
PhGA included assessment of severity of arthritis pain where physicians were asked to rate the severity of the participant's overall arthritis. The physician's response was recorded using a visual analog scale between 0 mm (very good condition) to 100 mm (very poor condition). Higher scores indicate higher degree of arthritis.
Time frame: Baseline, Day 7, 14
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Version 2.0 (V2) at Day 14
SF-36 is a standardized survey evaluating 8 aspects of functional health and well-being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. Score for each of the 8 aspects are scaled from 0 (worst condition) to 100 (best condition), where higher scores indicate better health status. These 8 domains were also reported as two summary scores: physical component scores and mental component scores. Score range for each of the 2 summary scores = 0 (worst condition) to 100 (best condition), where higher scores represent better health status.
Time frame: Baseline, Day 14 (D14)
Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Day 7, 14 and 42
DAS28-3 (CRP) was calculated from the swollen joint count and tender joint count using the 28 joints count and CRP (normal range of CRP is \<10 mg/L, decrease in the level of CRP indicates reduction in inflammation). Total DAS28-3 (CRP) score range: 0 (least severe) to 9.4 (most severe), higher scores indicate more disease activity.
Time frame: Baseline, Day 7, 14, 42
Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (4 Variables) (DAS28-4 [CRP]) at Day 7
DAS28-4 (CRP) examines progression or improvement of RA. It was assessed from SJC and TJC using the 28 joints count, CRP (normal range of CRP is \<10 mg/L, decrease in the level of CRP indicates reduction in inflammation) and PGA of disease activity (participant global assessment of diseases condition scores ranging from 0 \[very well condition\] to 100 \[very poor condition\], higher scores indicated greater affectation due to disease activity). Total DAS28-4 (CRP) transformed score range: 0 (least severe) to 10 (most severe), higher scores indicate more severe disease activity. DAS28-4 (CRP) scores: \<=3.2 implied low disease activity; \>3.2 to 5.1 implied moderate to high disease activity.
Time frame: Baseline, Day 7
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Day 7 and 14
ACR20 responder: participants who achieved at =20% improvement in tender and swollen 28-joints count, and \>=20% improvement in at least 3 of the following 5 measures: 1) participant's assessment of arthritis pain (participant's self-assessed severity of arthritis pain, score range from 0\[no pain\] to 100\[most severe pain\], higher scores=more pain), 2) PGA of arthritis (participant's assessed overall arthritis activity, score range from 0\[no arthritis\] to 100\[extreme arthritis\], higher scores=higher degree of arthritis), 3) PhGA of arthritis (physician rated severity of participants overall arthritis activity, score range from 0\[no arthritis\] to 100\[extreme arthritis\], higher scores=higher degree of arthritis), 4) HAQ-DI (assessment of functional disability, score range from 0\[no difficulty\] to 3\[extreme difficulty\], higher scores=more functional limitation) and 5) CRP (assessment of inflammation, normal range of CRP is \<10 mg/L, decrease in the level of CRP=reduction in inflammation).
Time frame: Day 7, 14
Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Day 7 and 14
ACR50 responder: participants who achieved at =50% improvement in tender and swollen 28-joints count, and \>=50% improvement in at least 3 of the following 5 measures: 1) participant's assessment of arthritis pain (participant's self-assessed severity of arthritis pain, score range from 0\[no pain\] to 100\[most severe pain\], higher scores=more pain), 2) PGA of arthritis (participant's assessed overall arthritis activity, score range from 0\[no arthritis\] to 100\[extreme arthritis\], higher scores=higher degree of arthritis), 3) PhGA of arthritis (physician rated severity of participants overall arthritis activity, score range from 0\[no arthritis\] to 100\[extreme arthritis\], higher scores=higher degree of arthritis), 4) HAQ-DI (assessment of functional disability, score range from 0\[no difficulty\] to 3\[extreme difficulty\], higher scores=more functional limitation) and 5) CRP (assessment of inflammation, normal range of CRP is \<10 mg/L, decrease in the level of CRP=reduction in inflammation).
Time frame: Day 7, 14
Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response at Day 7 and 14
ACR70 responder: participants who achieved at =70% improvement in tender and swollen 28-joints count, and \>=70% improvement in at least 3 of the following 5 measures: 1) participant's assessment of arthritis pain (participant's self-assessed severity of arthritis pain, score range from 0\[no pain\] to 100\[most severe pain\], higher scores=more pain), 2) PGA of arthritis (participant's assessed overall arthritis activity, score range from 0\[no arthritis\] to 100\[extreme arthritis\], higher scores=higher degree of arthritis), 3) PhGA of arthritis (physician rated severity of participants overall arthritis activity, score range from 0\[no arthritis\] to 100\[extreme arthritis\], higher scores=higher degree of arthritis), 4) HAQ-DI (assessment of functional disability, score range from 0\[no difficulty\] to 3\[extreme difficulty\], higher scores=more functional limitation) and 5) CRP (assessment of inflammation, normal range of CRP is \<10 mg/L, decrease in the level of CRP=reduction in inflammation).
Time frame: Day 7, 14
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 31 days after last dose (Day 45) that were absent before treatment or that worsened relative to pretreatment state.
Time frame: Baseline up to Day 45
Number of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities
Criteria for laboratory abnormalities: Hematology (hemoglobin, hematocrit \<0.8\*baseline; platelet count \<75 or \>700\*10\^3 per mm\^3; leucocytes \<2.5 or \>17.5\*10\^3 per mm\^3); chemistry (total bilirubin \>1.5\*upper limit of reference range \[ULN\]; aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transpeptidase, alkaline phosphatase, \>3.0\*ULN; total protein, albumin \<0.8\*lower limit of reference range \[LLN\] or \>1.2\*ULN; blood urea nitrogen \[BUN\]/urea, creatinine \>1.3\*ULN; glucose \[fasting\] \<0.6\*LLN or \>1.5\*ULN; uric acid \>1.2\*ULN; sodium \<0.95\*LLN or \>1.05\*ULN; potassium, calcium \<0.9\*LLN or \>1.1\*ULN; albumin, total protein \<0.8\*LLN or \>1.2\*ULN; urinalysis (urine white blood cell (WBC) =\>6/ high power field (hpf); urine red blood cell (RBC) =\>6/hpf). Number of participants with clinically significant change from baseline in laboratory abnormalities identified by investigator were reported.
Time frame: Baseline up to Day 45
Change From Baseline in Body Weight at Day 7 and 14
Time frame: Baseline, Day 7, 14
Number of Participants With Clinically Significant Vital Signs Abnormalities
Following parameters were analyzed for examination of vital signs: systolic and diastolic blood pressure, heart rate and body temperature. Vital sign measurements were performed with the participant in the seated position. Clinical significance vital sign abnormality was determined by investigator.
Time frame: Baseline up to Day 45
Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities
Clinically significant ECG findings included PR interval \>=300 milliseconds (msec) or \>=25% increase from baseline (if baseline PR interval \>200 msec) or \>=50% increase (if baseline PR interval less than or equal to \[\<=\] 200 msec); QRS interval \>=200 msec or \>=25% increase from baseline (if baseline PR interval \>100 msec) or \>=50% increase (if baseline PR interval \<= 100 msec); QT interval \>=500 msec, corrected QT interval \>=500 msec.
Time frame: Baseline up to Day 45
Plasma Concentration of PF-00251802 Versus Time Summary on Day 7 and Day 14
Plasma concentration of PF-00251802 versus time summary, a metabolite of PF-04171327 was reported in this outcome measure.
Time frame: 0, 1, 2, 3 and 4 hours post-dose on Day 7, 14
Ratio of Apparent Oral Clearance on Day 1 to Day 14 of Methotrexate
Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. Methotrexate was used as a background therapy by participants.
Time frame: Pre-dose (0 hour), 1, 2, 3 and 4 hours post-dose
Change From Baseline in Lymphocyte Counts at Day 1, 7 and 14
Time frame: Baseline; 1, 2, 3 and 4 hours post-dose on Day 1; 0, 1, 2, 3 and 4 hours post-dose on Day 7 and 14
Change From Baseline in Neutrophil Counts at Day 1, 7 and 14
Time frame: Baseline; 1, 2, 3 and 4 hours post-dose on Day 1; 0, 1, 2, 3 and 4 hours post-dose on Day 7 and 14
Change From Baseline in Eosinophil Counts at Day 1, 7 and 14
Time frame: Baseline; 1, 2, 3 and 4 hours post-dose on Day 1; 0, 1, 2, 3 and 4 hours post-dose on Day 7 and 14
Change From Baseline in Osteocalcin Level at Day 1, 7 and 14
Time frame: Baseline; 1, 2, 3 and 4 hours post-dose on Day 1; 0, 1, 2, 3 and 4 hours post-dose on Day 7 and 14
Change From Baseline in Plasma Cortisol Level at Day 1, 7 and 14
Time frame: Baseline; 1, 2, 3 and 4 hours post-dose on Day 1; 0, 1, 2, 3 and 4 hours post-dose on Day 7 and 14
Change From Baseline in Ratio of Urinary N-terminal Telopeptide of Type 1 Collagen (uNTX-I) Level to Urinary Creatinine (uCr) Level at Day 7 and 14
Unit of ratio of urinary N-terminal telopeptide of type 1 collagen (uNTX-I) level to urinary creatinine (uCr) level was nanomoles bone collagen equivalents (nmol bce) per millimole creatinine (mmol cr).
Time frame: Baseline, Day 7 and 14
Change From Baseline in Adiponectin Level at Day 7 and 14
Time frame: Baseline, Day 7 and 14
| Milestone | PF-04171327 10 mg + Placebo | PF-04171327 25 mg + Placebo | Prednisone 5 mg + Placebo | Placebo |
|---|---|---|---|---|
| Started | 21 | 22 | 21 | 22 |
| Completed | 18 | 21 | 20 | 20 |
| Not completed | 3 | 1 | 1 | 2 |
| Withdrew: Adverse event | 2 | 0 | 0 | 2 |
| Withdrew: Did not meet entrance criteria | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 | 0 |
DAS28-4 (CRP) examines progression or improvement of RA. It was assessed from swollen joint count (SJC) and tender joint count (TJC) using the 28 joints count, CRP (normal range of CRP is less than (\<) 10 milligram per liter \[mg/L\], decrease in the level of CRP indicates reduction in inflammation) and participant global assessment (PGA) of disease activity (participant global assessment of diseases condition scores ranging from 0 \[very well condition\] to 100 \[very poor condition\], higher scores indicated greater affectation due to disease activity). Total DAS28-4 (CRP) transformed score range: 0 (least severe) to 10 (most severe), higher scores indicate more severe disease activity. DAS28-4 (CRP) scores: less than equal to (\<=) 3.2 implied low disease activity; greater than (\>) 3.2 to 5.1 implied moderate to high disease activity.
| units on a scale | PF-04171327 10 mg + Placebo | PF-04171327 25 mg + Placebo | Prednisone 5 mg + Placebo | Placebo |
|---|---|---|---|---|
| Baseline | 6.04 ± 0.869 | 6.14 ± 0.755 | 5.92 ± 0.658 | 6.03 ± 0.810 |
| Change at Day 14 | -1.79 ± 0.916 | -2.22 ± 1.307 | -1.15 ± 0.935 | -0.96 ± 0.970 |
Number of tender joints was determined by examining 28 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1.
| tender joints | PF-04171327 10 mg + Placebo | PF-04171327 25 mg + Placebo | Prednisone 5 mg + Placebo | Placebo |
|---|---|---|---|---|
| Baseline | 17.10 ± 6.670 | 16.86 ± 5.375 | 15.05 ± 4.489 | 17.09 ± 6.023 |
| Change at Day 7 | -5.14 ± 6.807 | -5.95 ± 5.617 | -3.05 ± 4.117 | -4.18 ± 4.584 |
| Change at Day 14 | -7.22 ± 6.367 | -8.14 ± 6.755 | -4.15 ± 7.569 | -5.67 ± 6.807 |
| Change at Day 42 | -5.21 ± 6.188 | -6.52 ± 6.743 | -5.10 ± 6.703 | -6.81 ± 5.733 |
Number of swollen joints was determined by examination of 28 joints and identifying if swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1.
| swollen joints | PF-04171327 10 mg + Placebo | PF-04171327 25 mg + Placebo | Prednisone 5 mg + Placebo | Placebo |
|---|---|---|---|---|
| Baseline | 11.95 ± 4.717 | 11.73 ± 4.038 | 10.67 ± 3.554 | 11.64 ± 4.065 |
| Change at Day 7 | -3.19 ± 3.544 | -5.19 ± 4.045 | -2.90 ± 3.048 | -2.91 ± 3.963 |
| Change at Day 14 | -5.50 ± 3.777 | -6.71 ± 4.256 | -4.85 ± 3.133 | -5.24 ± 4.816 |
| Change at Day 42 | -3.26 ± 3.679 | -4.81 ± 4.167 | -6.15 ± 3.787 | -4.71 ± 4.900 |
The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. Normal range of CRP is less than (\<) 10 mg/L. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.
| mg/L | PF-04171327 10 mg + Placebo | PF-04171327 25 mg + Placebo | Prednisone 5 mg + Placebo | Placebo |
|---|---|---|---|---|
| Baseline | 20.24 ± 16.431 | 30.15 ± 35.396 | 20.02 ± 14.022 | 16.97 ± 19.580 |
| Change at Day 7 | -13.78 ± 18.208 | -23.60 ± 32.808 | -4.64 ± 18.487 | 1.31 ± 16.374 |
| Change at Day 14 | -18.13 ± 17.519 | -24.12 ± 33.273 | -7.63 ± 16.876 | -1.32 ± 10.357 |
| Change at Day 42 | 3.14 ± 28.198 | -13.09 ± 27.448 | -8.02 ± 13.850 | -5.11 ± 23.304 |
HAQ-DI assessed the ability of participants to perform task in 8 domains of daily living activities: dress/groom, arise, eat, walk, reach, grip, hygiene, and common activities. Each item was scored on a 4-point scale ranging from 0 to 3: 0= no difficulty; 1= some difficulty; 2= much difficulty; 3= unable to do, higher scores indicate more difficulty. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible HAQ-DI score range: 0 (no difficulty) to 3 (extreme difficulty), where higher scores indicate more difficulty while performing daily living activities.
| units on a scale | PF-04171327 10 mg + Placebo | PF-04171327 25 mg + Placebo | Prednisone 5 mg + Placebo | Placebo |
|---|---|---|---|---|
| Baseline | 1.76 ± 0.831 | 1.41 ± 0.796 | 1.62 ± 0.498 | 1.73 ± 0.935 |
| Change at Day 7 | -0.24 ± 0.700 | -0.24 ± 0.700 | -0.24 ± 0.436 | -0.10 ± 0.539 |
| Change at Day 14 | -0.58 ± 1.017 | -0.43 ± 0.870 | -0.25 ± 0.550 | -0.24 ± 0.768 |
Participant assessment of arthritis pain included assessment of severity of arthritis pain using a 100 millimeter (mm) visual analog scale (VAS). Participants placed a mark on the VAS between 0 mm (no pain) and 100 mm (most severe pain), which corresponded to the magnitude of their pain, higher scores indicate more pain.
| mm | PF-04171327 10 mg + Placebo | PF-04171327 25 mg + Placebo | Prednisone 5 mg + Placebo | Placebo |
|---|---|---|---|---|
| Baseline | 62.45 ± 25.586 | 60.49 ± 21.123 | 63.17 ± 15.551 | 66.65 ± 15.368 |
| Change at Day 7 | -12.03 ± 23.584 | -16.95 ± 25.056 | -8.67 ± 18.343 | -11.00 ± 21.889 |
| Change at Day 14 | -25.83 ± 31.899 | -27.29 ± 25.823 | -21.47 ± 23.627 | -14.69 ± 23.718 |
PGA was a questionnaire where participants answered the following question, "Considering all the ways your arthritis affects you, how are you feeling today?" The participants' response were recorded using a 100 mm visual analog scale placing a mark on the scale, between 0 mm (very well condition) to 100 mm (very poor condition). Higher scores indicate higher degree of arthritis.
| mm | PF-04171327 10 mg + Placebo | PF-04171327 25 mg + Placebo | Prednisone 5 mg + Placebo | Placebo |
|---|---|---|---|---|
| Baseline | 60.71 ± 24.265 | 63.55 ± 20.589 | 65.89 ± 14.957 | 65.26 ± 18.426 |
| Change at Day 7 | -16.05 ± 21.800 | -18.75 ± 25.933 | -11.87 ± 17.036 | -7.94 ± 21.281 |
| Change at Day 14 | -22.63 ± 30.656 | -27.97 ± 26.894 | -22.43 ± 22.303 | -11.77 ± 27.457 |
PhGA included assessment of severity of arthritis pain where physicians were asked to rate the severity of the participant's overall arthritis. The physician's response was recorded using a visual analog scale between 0 mm (very good condition) to 100 mm (very poor condition). Higher scores indicate higher degree of arthritis.
| mm | PF-04171327 10 mg + Placebo | PF-04171327 25 mg + Placebo | Prednisone 5 mg + Placebo | Placebo |
|---|---|---|---|---|
| Baseline | 58.10 ± 19.917 | 62.27 ± 13.016 | 57.86 ± 13.309 | 59.87 ± 15.194 |
| Change at Day 7 | -13.38 ± 22.295 | -20.42 ± 16.487 | -9.71 ± 13.723 | -13.58 ± 16.208 |
| Change at Day 14 | -22.16 ± 23.176 | -32.19 ± 19.473 | -20.90 ± 18.671 | -14.87 ± 21.176 |
SF-36 is a standardized survey evaluating 8 aspects of functional health and well-being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. Score for each of the 8 aspects are scaled from 0 (worst condition) to 100 (best condition), where higher scores indicate better health status. These 8 domains were also reported as two summary scores: physical component scores and mental component scores. Score range for each of the 2 summary scores = 0 (worst condition) to 100 (best condition), where higher scores represent better health status.
| units on a scale | PF-04171327 10 mg + Placebo | PF-04171327 25 mg + Placebo | Prednisone 5 mg + Placebo | Placebo |
|---|---|---|---|---|
| Baseline: Physical functioning | 29.92 ± 9.624 | 30.69 ± 8.305 | 29.14 ± 7.187 | 32.74 ± 9.904 |
| Change at D14: Physical functioning | 4.52 ± 9.142 | 4.58 ± 6.660 | 4.71 ± 6.543 | 0.51 ± 10.968 |
| Baseline: Role physical | 35.72 ± 9.452 | 35.69 ± 8.680 | 33.10 ± 7.288 | 34.28 ± 10.031 |
| Change at D14: Role physical | 4.27 ± 12.182 | 7.27 ± 9.378 | 5.01 ± 6.789 | 5.97 ± 10.516 |
| Baseline: Bodily pain | 31.41 ± 7.473 | 32.88 ± 6.234 | 31.35 ± 4.159 | 33.43 ± 6.851 |
| Change at D14: Bodily pain | 11.25 ± 11.394 | 11.60 ± 7.609 | 7.73 ± 6.435 | 4.33 ± 11.369 |
| Baseline: General health | 30.91 ± 9.564 | 37.33 ± 11.005 | 35.36 ± 8.423 | 35.43 ± 9.408 |
| Change at D14: General health | 4.40 ± 6.604 | 3.96 ± 5.853 | 3.31 ± 5.652 | 4.09 ± 6.740 |
| Baseline: Vitality | 38.98 ± 10.166 | 42.43 ± 9.891 | 39.70 ± 8.671 | 39.98 ± 8.567 |
| Change at D14: Vitality | 7.88 ± 11.603 | 7.70 ± 7.183 | 4.79 ± 7.229 | 4.19 ± 10.962 |
| Baseline: Social functioning | 39.50 ± 10.384 | 39.05 ± 12.411 | 34.89 ± 9.468 | 35.87 ± 11.809 |
| Change at D14: Social functioning | 4.25 ± 10.988 | 7.68 ± 9.090 | 5.65 ± 5.647 | 4.57 ± 10.934 |
| Baseline: Role emotional | 36.39 ± 13.164 | 37.95 ± 12.978 | 35.49 ± 12.287 | 35.37 ± 14.477 |
| Change at D14: Role emotional | 5.18 ± 15.873 | 6.31 ± 12.051 | 2.65 ± 12.888 | 2.65 ± 14.538 |
| Baseline: Mental health | 37.71 ± 14.742 | 42.40 ± 11.681 | 37.97 ± 11.807 | 36.23 ± 12.871 |
| Change at D14: Mental health | 7.00 ± 15.072 | 4.62 ± 9.368 | 5.13 ± 8.540 | 2.49 ± 11.819 |
| Baseline: Physical component | 30.89 ± 7.342 | 32.05 ± 6.627 | 30.91 ± 5.185 | 33.93 ± 6.554 |
| Change at D14: Physical component | 5.74 ± 6.611 | 7.10 ± 4.351 | 5.49 ± 5.219 | 3.73 ± 8.594 |
| Baseline: Mental component | 41.19 ± 14.648 | 44.42 ± 13.036 | 40.30 ± 12.464 | 38.55 ± 13.064 |
| Change at D14: Mental component | 5.91 ± 14.065 | 5.72 ± 9.743 | 3.78 ± 8.358 | 3.24 ± 12.812 |
DAS28-3 (CRP) was calculated from the swollen joint count and tender joint count using the 28 joints count and CRP (normal range of CRP is \<10 mg/L, decrease in the level of CRP indicates reduction in inflammation). Total DAS28-3 (CRP) score range: 0 (least severe) to 9.4 (most severe), higher scores indicate more disease activity.
| units on a scale | PF-04171327 10 mg + Placebo | PF-04171327 25 mg + Placebo | Prednisone 5 mg + Placebo | Placebo |
|---|---|---|---|---|
| Baseline | 5.80 ± 0.731 | 5.87 ± 0.674 | 5.59 ± 0.666 | 5.72 ± 0.706 |
| Change at Day 7 | -1.07 ± 0.800 | -1.51 ± 0.845 | -0.55 ± 0.632 | -0.50 ± 0.609 |
| Change at Day 14 | -1.57 ± 0.749 | -2.01 ± 1.178 | -0.92 ± 0.994 | -0.87 ± 0.798 |
| Change at Day 42 | -0.81 ± 1.007 | -1.26 ± 1.199 | -1.17 ± 0.949 | -1.12 ± 1.005 |
DAS28-4 (CRP) examines progression or improvement of RA. It was assessed from SJC and TJC using the 28 joints count, CRP (normal range of CRP is \<10 mg/L, decrease in the level of CRP indicates reduction in inflammation) and PGA of disease activity (participant global assessment of diseases condition scores ranging from 0 \[very well condition\] to 100 \[very poor condition\], higher scores indicated greater affectation due to disease activity). Total DAS28-4 (CRP) transformed score range: 0 (least severe) to 10 (most severe), higher scores indicate more severe disease activity. DAS28-4 (CRP) scores: \<=3.2 implied low disease activity; \>3.2 to 5.1 implied moderate to high disease activity.
| units on a scale | PF-04171327 10 mg + Placebo | PF-04171327 25 mg + Placebo | Prednisone 5 mg + Placebo | Placebo |
|---|---|---|---|---|
| Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (4 Variables) (DAS28-4 [CRP]) at Day 7 | -1.21 ± 0.889 | -1.63 ± 1.034 | -0.67 ± 0.639 | -0.55 ± 0.697 |
ACR20 responder: participants who achieved at =20% improvement in tender and swollen 28-joints count, and \>=20% improvement in at least 3 of the following 5 measures: 1) participant's assessment of arthritis pain (participant's self-assessed severity of arthritis pain, score range from 0\[no pain\] to 100\[most severe pain\], higher scores=more pain), 2) PGA of arthritis (participant's assessed overall arthritis activity, score range from 0\[no arthritis\] to 100\[extreme arthritis\], higher scores=higher degree of arthritis), 3) PhGA of arthritis (physician rated severity of participants overall arthritis activity, score range from 0\[no arthritis\] to 100\[extreme arthritis\], higher scores=higher degree of arthritis), 4) HAQ-DI (assessment of functional disability, score range from 0\[no difficulty\] to 3\[extreme difficulty\], higher scores=more functional limitation) and 5) CRP (assessment of inflammation, normal range of CRP is \<10 mg/L, decrease in the level of CRP=reduction in inflammation).
| percentage of participants | PF-04171327 10 mg + Placebo | PF-04171327 25 mg + Placebo | Prednisone 5 mg + Placebo | Placebo |
|---|---|---|---|---|
| Day 7 | 28.57 | 52.38 | 14.29 | 27.27 |
| Day 14 | 55.56 | 66.67 | 45.00 | 38.10 |
ACR50 responder: participants who achieved at =50% improvement in tender and swollen 28-joints count, and \>=50% improvement in at least 3 of the following 5 measures: 1) participant's assessment of arthritis pain (participant's self-assessed severity of arthritis pain, score range from 0\[no pain\] to 100\[most severe pain\], higher scores=more pain), 2) PGA of arthritis (participant's assessed overall arthritis activity, score range from 0\[no arthritis\] to 100\[extreme arthritis\], higher scores=higher degree of arthritis), 3) PhGA of arthritis (physician rated severity of participants overall arthritis activity, score range from 0\[no arthritis\] to 100\[extreme arthritis\], higher scores=higher degree of arthritis), 4) HAQ-DI (assessment of functional disability, score range from 0\[no difficulty\] to 3\[extreme difficulty\], higher scores=more functional limitation) and 5) CRP (assessment of inflammation, normal range of CRP is \<10 mg/L, decrease in the level of CRP=reduction in inflammation).
| percentage of participants | PF-04171327 10 mg + Placebo | PF-04171327 25 mg + Placebo | Prednisone 5 mg + Placebo | Placebo |
|---|---|---|---|---|
| Day 7 | 9.52 | 19.05 | 0.00 | 0.00 |
| Day 14 | 22.22 | 47.62 | 20.00 | 14.29 |
ACR70 responder: participants who achieved at =70% improvement in tender and swollen 28-joints count, and \>=70% improvement in at least 3 of the following 5 measures: 1) participant's assessment of arthritis pain (participant's self-assessed severity of arthritis pain, score range from 0\[no pain\] to 100\[most severe pain\], higher scores=more pain), 2) PGA of arthritis (participant's assessed overall arthritis activity, score range from 0\[no arthritis\] to 100\[extreme arthritis\], higher scores=higher degree of arthritis), 3) PhGA of arthritis (physician rated severity of participants overall arthritis activity, score range from 0\[no arthritis\] to 100\[extreme arthritis\], higher scores=higher degree of arthritis), 4) HAQ-DI (assessment of functional disability, score range from 0\[no difficulty\] to 3\[extreme difficulty\], higher scores=more functional limitation) and 5) CRP (assessment of inflammation, normal range of CRP is \<10 mg/L, decrease in the level of CRP=reduction in inflammation).
| percentage of participants | PF-04171327 10 mg + Placebo | PF-04171327 25 mg + Placebo | Prednisone 5 mg + Placebo | Placebo |
|---|---|---|---|---|
| Day 7 | 4.76 | 4.76 | 0.00 | 0.00 |
| Day 14 | 0.00 | 14.29 | 0.00 | 0.00 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 31 days after last dose (Day 45) that were absent before treatment or that worsened relative to pretreatment state.
| participants | PF-04171327 10 mg + Placebo | PF-04171327 25 mg + Placebo | Prednisone 5 mg + Placebo | Placebo |
|---|---|---|---|---|
| AE | 8 | 3 | 4 | 12 |
| SAE | 0 | 0 | 0 | 0 |
Criteria for laboratory abnormalities: Hematology (hemoglobin, hematocrit \<0.8\*baseline; platelet count \<75 or \>700\*10\^3 per mm\^3; leucocytes \<2.5 or \>17.5\*10\^3 per mm\^3); chemistry (total bilirubin \>1.5\*upper limit of reference range \[ULN\]; aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transpeptidase, alkaline phosphatase, \>3.0\*ULN; total protein, albumin \<0.8\*lower limit of reference range \[LLN\] or \>1.2\*ULN; blood urea nitrogen \[BUN\]/urea, creatinine \>1.3\*ULN; glucose \[fasting\] \<0.6\*LLN or \>1.5\*ULN; uric acid \>1.2\*ULN; sodium \<0.95\*LLN or \>1.05\*ULN; potassium, calcium \<0.9\*LLN or \>1.1\*ULN; albumin, total protein \<0.8\*LLN or \>1.2\*ULN; urinalysis (urine white blood cell (WBC) =\>6/ high power field (hpf); urine red blood cell (RBC) =\>6/hpf). Number of participants with clinically significant change from baseline in laboratory abnormalities identified by investigator were reported.
| participants | PF-04171327 10 mg + Placebo | PF-04171327 25 mg + Placebo | Prednisone 5 mg + Placebo | Placebo |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities | 0 | 0 | 0 | 0 |
| kilogram | PF-04171327 10 mg + Placebo | PF-04171327 25 mg + Placebo | Prednisone 5 mg + Placebo | Placebo |
|---|---|---|---|---|
| Baseline | 83.7 ± 17.0 | 74.1 ± 16.1 | 78.4 ± 15.4 | 75.0 ± 17.2 |
| Change at Day 7 | 0.12 ± 0.733 | -0.04 ± 1.256 | -0.02 ± 1.036 | -0.05 ± 0.858 |
| Change at Day 14 | 0.35 ± 1.064 | 0.20 ± 1.158 | 0.18 ± 1.467 | -0.04 ± 0.903 |
Following parameters were analyzed for examination of vital signs: systolic and diastolic blood pressure, heart rate and body temperature. Vital sign measurements were performed with the participant in the seated position. Clinical significance vital sign abnormality was determined by investigator.
| participants | PF-04171327 10 mg + Placebo | PF-04171327 25 mg + Placebo | Prednisone 5 mg + Placebo | Placebo |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Vital Signs Abnormalities | 0 ± 6.55 | 0 ± 7.78 | 0 ± 7.30 | 0 ± 7.54 |
Clinically significant ECG findings included PR interval \>=300 milliseconds (msec) or \>=25% increase from baseline (if baseline PR interval \>200 msec) or \>=50% increase (if baseline PR interval less than or equal to \[\<=\] 200 msec); QRS interval \>=200 msec or \>=25% increase from baseline (if baseline PR interval \>100 msec) or \>=50% increase (if baseline PR interval \<= 100 msec); QT interval \>=500 msec, corrected QT interval \>=500 msec.
| participants | PF-04171327 10 mg + Placebo | PF-04171327 25 mg + Placebo | Prednisone 5 mg + Placebo | Placebo |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities | 0 | 0 | 0 | 0 |
Plasma concentration of PF-00251802 versus time summary, a metabolite of PF-04171327 was reported in this outcome measure.
| nanogram per milliliter (ng/mL) | PF-04171327 10 mg + Placebo | PF-04171327 25 mg + Placebo |
|---|---|---|
| Day 7 (0 hour) | 53.07 ± 21.480 | 136.8 ± 82.246 |
| Day 7 (1 hour) | 90.28 ± 50.250 | 257.9 ± 93.716 |
| Day 7 (2 hour) | 118.1 ± 40.314 | 281.3 ± 73.866 |
| Day 7 (3 hour) | 116.3 ± 42.988 | 230.7 ± 82.895 |
| Day 7 (4 hour) | 107.5 ± 27.303 | 220.6 ± 53.416 |
| Day 14 (0 hour) | 53.94 ± 25.382 | 136.3 ± 53.159 |
| Day 14 (1 hour) | 115.7 ± 64.846 | 216.4 ± 102.88 |
| Day 14 (2 hour) | 133.9 ± 50.294 | 284.9 ± 117.38 |
| Day 14 (3 hour) | 123.7 ± 36.720 | 296.6 ± 119.76 |
| Day 14 (4 hour) | 106.3 ± 28.542 | 243.3 ± 90.962 |
Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. Methotrexate was used as a background therapy by participants.
| ratio | PF-04171327 10 mg + Placebo | PF-04171327 25 mg + Placebo | Prednisone 5 mg + Placebo | Placebo |
|---|---|---|---|---|
| Ratio of Apparent Oral Clearance on Day 1 to Day 14 of Methotrexate | 1.24 ± 0.12 | 0.98 ± 0.05 | 1.14 ± 0.10 | 0.93 ± 0.07 |
| 10^3 cells per microliter | PF-04171327 10 mg + Placebo | PF-04171327 25 mg + Placebo | Prednisone 5 mg + Placebo | Placebo |
|---|---|---|---|---|
| Baseline | 1.85 ± 0.510 | 1.80 ± 0.856 | 1.68 ± 0.560 | 1.79 ± 0.648 |
| Change at Day 1: 1 hour | -0.01 ± 0.200 | 0.02 ± 0.304 | 0.13 ± 0.344 | 0.04 ± 0.218 |
| Change at Day 1: 2 hour | 0.28 ± 0.315 | 0.05 ± 0.320 | 0.09 ± 0.326 | 0.09 ± 0.231 |
| Change at Day 1: 3 hour | 0.21 ± 0.322 | 0.07 ± 0.328 | 0.10 ± 0.297 | 0.04 ± 0.455 |
| Change at Day 1: 4 hour | 0.28 ± 0.408 | 0.05 ± 0.428 | 0.07 ± 0.244 | 0.03 ± 0.450 |
| Change at Day 7: 0 hour | 0.79 ± 0.384 | 0.83 ± 0.342 | 0.26 ± 0.441 | 0.05 ± 0.270 |
| Change at Day 7: 1 hour | 0.64 ± 0.477 | 0.62 ± 0.438 | 0.13 ± 0.589 | -0.03 ± 0.275 |
| Change at Day 7: 2 hour | 0.76 ± 0.416 | 0.76 ± 0.463 | -0.03 ± 0.505 | 0.10 ± 0.287 |
| Change at Day 7: 3 hour | 0.77 ± 0.465 | 0.85 ± 0.563 | -0.25 ± 0.539 | 0.15 ± 0.345 |
| Change at Day 7: 4 hour | 0.72 ± 0.470 | 0.69 ± 0.478 | -0.23 ± 0.431 | 0.19 ± 0.402 |
| Change at Day 14: 0 hour | 0.89 ± 0.308 | 0.82 ± 0.638 | 0.29 ± 0.492 | -0.07 ± 0.322 |
| Change at Day 14: 1 hour | 0.81 ± 0.425 | 0.66 ± 0.589 | 0.22 ± 0.421 | -0.03 ± 0.294 |
| Change at Day 14: 2 hour | 0.74 ± 0.340 | 0.62 ± 0.680 | -0.03 ± 0.467 | 0.04 ± 0.441 |
| Change at Day 14: 3 hour | 0.81 ± 0.494 | 0.75 ± 0.634 | -0.35 ± 0.397 | 0.20 ± 0.238 |
| Change at Day 14: 4 hour | 0.77 ± 0.428 | 0.57 ± 0.445 | -0.45 ± 0.396 | 0.08 ± 0.268 |
| 10^3 cells per microliter | PF-04171327 10 mg + Placebo | PF-04171327 25 mg + Placebo | Prednisone 5 mg + Placebo | Placebo |
|---|---|---|---|---|
| Baseline | 5.43 ± 2.050 | 5.53 ± 3.091 | 5.90 ± 2.127 | 5.03 ± 2.029 |
| Change at Day 1: 1 hour | 0.04 ± 0.799 | 0.42 ± 0.581 | 0.45 ± 0.853 | 0.09 ± 0.534 |
| Change at Day 1: 2 hour | 0.01 ± 0.516 | 0.12 ± 0.621 | 0.38 ± 1.109 | -0.07 ± 0.674 |
| Change at Day 1: 3 hour | -0.06 ± 0.638 | 0.49 ± 1.247 | 0.22 ± 0.999 | -0.05 ± 0.812 |
| Change at Day 1: 4 hour | -0.28 ± 0.876 | 0.34 ± 1.625 | -0.03 ± 0.984 | -0.25 ± 0.831 |
| Change at Day 7: 0 hour | 0.16 ± 1.036 | 0.06 ± 1.993 | 0.22 ± 1.401 | -0.21 ± 1.217 |
| Change at Day 7: 1 hour | 0.63 ± 1.145 | 0.21 ± 1.947 | 0.64 ± 1.776 | 0.07 ± 1.202 |
| Change at Day 7: 2 hour | 0.79 ± 1.195 | 0.80 ± 2.278 | 1.66 ± 1.764 | -0.06 ± 1.292 |
| Change at Day 7: 3 hour | 1.19 ± 1.304 | 1.19 ± 2.120 | 2.14 ± 1.828 | -0.13 ± 1.252 |
| Change at Day 7: 4 hour | 1.13 ± 1.320 | 0.84 ± 2.159 | 2.01 ± 1.788 | -0.47 ± 1.352 |
| Change at Day 14: 0 hour | 0.32 ± 0.954 | 0.77 ± 1.881 | -0.79 ± 1.291 | -0.11 ± 1.116 |
| Change at Day 14: 1 hour | 0.40 ± 1.114 | 1.00 ± 1.827 | -0.09 ± 1.566 | -0.16 ± 0.731 |
| Change at Day 14: 2 hour | 0.56 ± 1.172 | 1.11 ± 2.097 | 0.74 ± 1.866 | -0.35 ± 0.901 |
| Change at Day 14: 3 hour | 1.10 ± 1.560 | 1.57 ± 2.076 | 1.14 ± 1.788 | -0.41 ± 1.190 |
| Change at Day 14: 4 hour | 1.09 ± 1.559 | 1.39 ± 2.203 | 1.07 ± 1.595 | -0.65 ± 1.347 |
| 10^3 cells per microliter | PF-04171327 10 mg + Placebo | PF-04171327 25 mg + Placebo | Prednisone 5 mg + Placebo | Placebo |
|---|---|---|---|---|
| Baseline | 0.19 ± 0.115 | 0.19 ± 0.128 | 0.20 ± 0.094 | 0.15 ± 0.077 |
| Change at Day 1: 1 hour | -0.02 ± 0.069 | -0.02 ± 0.060 | -0.02 ± 0.034 | -0.00 ± 0.050 |
| Change at Day 1: 2 hour | -0.01 ± 0.039 | -0.01 ± 0.042 | -0.03 ± 0.038 | -0.00 ± 0.057 |
| Change at Day 1: 3 hour | -0.01 ± 0.039 | -0.01 ± 0.060 | -0.03 ± 0.039 | -0.00 ± 0.057 |
| Change at Day 1: 4 hour | -0.01 ± 0.072 | -0.03 ± 0.079 | -0.04 ± 0.043 | -0.01 ± 0.048 |
| Change at Day 7: 0 hour | -0.03 ± 0.081 | -0.04 ± 0.101 | -0.02 ± 0.055 | 0.00 ± 0.072 |
| Change at Day 7: 1 hour | -0.02 ± 0.050 | -0.03 ± 0.146 | -0.02 ± 0.056 | -0.01 ± 0.081 |
| Change at Day 7: 2 hour | -0.03 ± 0.059 | -0.07 ± 0.121 | -0.04 ± 0.078 | 0.01 ± 0.077 |
| Change at Day 7: 3 hour | -0.04 ± 0.063 | -0.08 ± 0.114 | -0.07 ± 0.087 | 0.00 ± 0.085 |
| Change at Day 7: 4 hour | -0.04 ± 0.070 | -0.06 ± 0.098 | -0.09 ± 0.091 | 0.00 ± 0.080 |
| Change at Day 14: 0 hour | -0.03 ± 0.048 | -0.05 ± 0.167 | -0.02 ± 0.073 | 0.01 ± 0.085 |
| Change at Day 14: 1 hour | -0.04 ± 0.052 | -0.05 ± 0.163 | -0.03 ± 0.076 | -0.01 ± 0.079 |
| Change at Day 14: 2 hour | -0.05 ± 0.063 | -0.07 ± 0.139 | -0.05 ± 0.074 | 0.01 ± 0.092 |
| Change at Day 14: 3 hour | -0.05 ± 0.063 | -0.07 ± 0.139 | -0.09 ± 0.091 | 0.01 ± 0.098 |
| Change at Day 14: 4 hour | -0.05 ± 0.065 | -0.07 ± 0.157 | -0.11 ± 0.096 | -0.01 ± 0.076 |
| ng/mL | PF-04171327 10 mg + Placebo | PF-04171327 25 mg + Placebo | Prednisone 5 mg + Placebo | Placebo |
|---|---|---|---|---|
| Baseline | 21.76 ± 13.031 | 17.52 ± 9.803 | 29.36 ± 46.812 | 15.29 ± 7.156 |
| Change at Day 1: 1 hour | -1.78 ± 2.012 | -1.45 ± 3.164 | -1.94 ± 2.897 | -0.50 ± 6.877 |
| Change at Day 1: 2 hour | -2.22 ± 2.344 | -2.07 ± 3.110 | -1.19 ± 4.445 | -0.73 ± 3.662 |
| Change at Day 1: 3 hour | -2.67 ± 3.063 | -1.07 ± 2.003 | -1.35 ± 3.355 | -1.30 ± 4.150 |
| Change at Day 1: 4 hour | -3.15 ± 2.964 | -1.77 ± 1.849 | -3.10 ± 5.281 | -0.93 ± 3.006 |
| Change at Day 7: 0 hour | -5.26 ± 5.312 | -3.82 ± 5.308 | -3.08 ± 3.995 | 0.69 ± 3.024 |
| Change at Day 7: 1 hour | -5.88 ± 4.719 | -4.42 ± 7.438 | -0.66 ± 6.633 | -0.37 ± 2.976 |
| Change at Day 7: 2 hour | -5.71 ± 4.842 | -4.22 ± 4.765 | -2.74 ± 5.384 | -0.52 ± 3.901 |
| Change at Day 7: 3 hour | -5.77 ± 7.349 | -3.68 ± 5.324 | -2.83 ± 5.194 | -0.33 ± 4.304 |
| Change at Day 7: 4 hour | -5.78 ± 6.145 | -3.87 ± 5.488 | -2.48 ± 6.523 | -1.05 ± 4.206 |
| Change at Day 14: 0 hour | -6.01 ± 6.184 | -4.56 ± 6.155 | -3.04 ± 6.087 | 0.63 ± 2.175 |
| Change at Day 14: 1 hour | -6.28 ± 6.197 | -4.90 ± 5.666 | -2.66 ± 5.289 | -0.25 ± 2.588 |
| Change at Day 14: 2 hour | -5.80 ± 5.833 | -5.11 ± 6.341 | -4.21 ± 5.936 | -0.35 ± 3.507 |
| Change at Day 14: 3 hour | -6.42 ± 6.142 | -5.74 ± 6.195 | -5.88 ± 10.958 | 0.56 ± 4.890 |
| Change at Day 14: 4 hour | -7.45 ± 7.144 | -5.40 ± 6.536 | -4.19 ± 4.398 | -0.41 ± 4.828 |
| ng/mL | PF-04171327 10 mg + Placebo | PF-04171327 25 mg + Placebo | Prednisone 5 mg + Placebo | Placebo |
|---|---|---|---|---|
| Baseline | 106.85 ± 27.404 | 110.50 ± 48.340 | 106.38 ± 41.396 | 105.14 ± 56.721 |
| Change at Day 1: 1 hour | -26.40 ± 26.238 | -30.94 ± 26.083 | -13.81 ± 28.559 | -27.71 ± 21.432 |
| Change at Day 1: 2 hour | -29.12 ± 36.305 | -37.17 ± 40.260 | -22.81 ± 36.158 | -32.92 ± 29.781 |
| Change at Day 1: 3 hour | -20.05 ± 42.714 | -24.19 ± 48.793 | -14.95 ± 41.651 | -21.80 ± 39.042 |
| Change at Day 1: 4 hour | -16.47 ± 35.633 | -21.05 ± 55.572 | -21.49 ± 32.521 | -9.16 ± 50.832 |
| Change at Day 7: 0 hour | -92.06 ± 32.334 | -103.76 ± 49.618 | 6.72 ± 24.388 | 7.20 ± 58.163 |
| Change at Day 7: 1 hour | -93.92 ± 30.165 | -104.69 ± 50.229 | -51.94 ± 32.569 | -25.39 ± 44.117 |
| Change at Day 7: 2 hour | -93.69 ± 30.420 | -104.96 ± 50.522 | -66.70 ± 33.932 | -35.19 ± 44.417 |
| Change at Day 7: 3 hour | -94.81 ± 31.049 | -105.01 ± 49.683 | -77.36 ± 33.208 | -26.69 ± 36.852 |
| Change at Day 7: 4 hour | -98.82 ± 26.955 | -104.69 ± 49.771 | -83.46 ± 34.019 | -20.38 ± 43.739 |
| Change at Day 14: 0 hour | -92.02 ± 37.108 | -104.86 ± 50.721 | -14.46 ± 29.806 | 3.49 ± 48.156 |
| Change at Day 14: 1 hour | -98.93 ± 29.046 | -105.41 ± 51.193 | -55.14 ± 39.771 | -25.38 ± 17.075 |
| Change at Day 14: 2 hour | -101.65 ± 27.335 | -105.70 ± 51.242 | -70.60 ± 33.658 | -33.54 ± 30.064 |
| Change at Day 14: 3 hour | -101.78 ± 27.765 | -105.29 ± 51.583 | -81.66 ± 35.573 | -23.01 ± 38.787 |
| Change at Day 14: 4 hour | -102.85 ± 27.210 | -105.25 ± 51.263 | -86.27 ± 37.588 | -24.87 ± 38.497 |
Unit of ratio of urinary N-terminal telopeptide of type 1 collagen (uNTX-I) level to urinary creatinine (uCr) level was nanomoles bone collagen equivalents (nmol bce) per millimole creatinine (mmol cr).
| nmol BCE/mmol cr | PF-04171327 10 mg + Placebo | PF-04171327 25 mg + Placebo | Prednisone 5 mg + Placebo | Placebo |
|---|---|---|---|---|
| Baseline | 63.56 ± 28.239 | 62.00 ± 26.946 | 77.75 ± 51.582 | 79.63 ± 51.794 |
| Change at Day 7 | 7.94 ± 16.482 | 16.40 ± 23.922 | -3.58 ± 29.632 | -13.42 ± 31.783 |
| Change at Day 14 | 11.79 ± 29.100 | 18.15 ± 19.626 | -3.84 ± 33.997 | -9.44 ± 33.369 |
| ng/mL | PF-04171327 10 mg + Placebo | PF-04171327 25 mg + Placebo | Prednisone 5 mg + Placebo | Placebo |
|---|---|---|---|---|
| Baseline | 7251.43 ± 3651.564 | 8349.09 ± 3105.632 | 7732.38 ± 3428.231 | 10080.95 ± 5136.660 |
| Change at Day 7 | -434.21 ± 3895.367 | 1664.76 ± 1651.925 | -12.00 ± 1274.931 | -430.95 ± 3049.383 |
| Change at Day 14 | 1023.16 ± 2203.248 | 2692.86 ± 2409.083 | 438.50 ± 951.189 | 193.16 ± 1965.254 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PF-04171327 10 mg + Placebo | — | 0/21 (0%) | 8/21 (38.1%) |
| PF-04171327 25 mg + Placebo | — | 0/22 (0%) | 3/22 (13.6%) |
| Prednisone 5 mg + Placebo | — | 0/21 (0%) | 4/21 (19%) |
| Placebo | — | 0/22 (0%) | 12/22 (54.5%) |
| Event | PF-04171327 10 mg + Placebo | PF-04171327 25 mg + Placebo | Prednisone 5 mg + Placebo | Placebo |
|---|---|---|---|---|
| HeadacheNervous system disorders | 0/21 | 0/22 | 2/21 | 4/22 |
| NasopharyngitisInfections and infestations | 1/21 | 0/22 | 2/21 | 0/22 |
| Upper respiratory tract infectionInfections and infestations | 2/21 | 0/22 | 0/21 | 0/22 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/21 | 0/22 | 1/21 | 2/22 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 0/21 | 0/22 | 0/21 | 2/22 |
| Disturbance in attentionNervous system disorders | 0/21 | 0/22 | 0/21 | 2/22 |
| RashSkin and subcutaneous tissue disorders | 0/21 | 0/22 | 0/21 | 2/22 |
| MenorrhagiaReproductive system and breast disorders | 0/14 | 1/12 | 0/15 | 0/20 |
| VertigoEar and labyrinth disorders | 1/21 | 0/22 | 0/21 | 0/22 |
| ConjunctivitisEye disorders | 1/21 | 0/22 | 0/21 | 0/22 |
The full analysis set (FAS) included all randomized participants who received at least 1 dose of the randomized investigational drug.
| Age, Continuous(years) | PF-04171327 10 mg + Placebo | PF-04171327 25 mg + Placebo | Prednisone 5 mg + Placebo | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 56.5 ± 12.2 | 55.6 ± 11.4 | 56.0 ± 8.4 | 53.8 ± 11.9 | 55.5 ± 10.9 |
| Sex: Female, Male(Participants) | PF-04171327 10 mg + Placebo | PF-04171327 25 mg + Placebo | Prednisone 5 mg + Placebo | Placebo | Total |
|---|---|---|---|---|---|
| Female | 14 | 12 | 15 | 20 | 61 |
| Male | 7 | 10 | 6 | 2 | 25 |
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Oct 2009 to primary completion in Jul 2010, 9 months.
Results were first posted in Nov 2023, 13 years 3 months after primary completion. A results delay was requested in Oct 2011.
Of 114 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 9 months is below that.
Counting every sponsor, half of 154 studies reached it within 18 months; a quarter within 13 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fosdagrocorat